XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.4
Summary of Significant Accounting Policies (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Accounting Policies [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [1] $ 33,632 $ (13,668) $ 13,063 $ (5,356)
Foreign Currency Transaction Gain (Loss), Realized [2] (2,107) 13,062 6,560 10,363
Other Nonoperating Gains (Losses) 153 215 563 1,021
Other income (expense), net 31,678 (391) 20,186 6,028
Realized gain (loss) on derivatives not designated as hedging instruments $ 2,981 [1] $ 2,539 $ 749 $ 488
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 60   $ 60  
Weighted average shares outstanding — diluted 25,906,151 27,179,073 26,145,452 27,129,264
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1) 940,539 569,144 [3] 1,078,723 589,915
Net Income (Loss) Per Share Attributable to Cimpress plc [Line Items]        
Weighted average shares outstanding — basic 24,965,612 26,609,929 25,066,729 26,539,349
Weighted average shares issuable upon exercise/vesting of outstanding share options/PSUs/RSUs/warrants (1) 940,539 569,144 [3] 1,078,723 589,915
Weighted average shares outstanding — diluted 25,906,151 27,179,073 26,145,452 27,129,264
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 299,877 192,204 153,799 189,927
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,055,377   1,055,377  
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 248,156 146,506 294,657 122,412
Foreign Exchange Forward [Member]        
Accounting Policies [Line Items]        
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net $ 33,632 $ (13,668) $ 13,063 $ (5,356)
[1] Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized gains of $2,981 and $749 for the three and six months ended December 31, 2024, respectively, and losses of $2,539 and $488 for the three and six months ended December 31, 2023, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
[2] Currency-related (losses) gains, net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, during the three and six months ended December 31, 2023, we recognized gains of $2,230 and $294, respectively, on a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. We did not hold any cross-currency swap contracts that were designated as cash flow hedges during the three and six months ended December 31, 2024. Refer to Note 4 for additional details regarding our cash flow hedges.
[3] On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. The weighted average dilutive effect of the warrants for the three and six months ended December 31, 2024 were 248,156 and 294,657, respectively, and for the three and six months ended December 31, 2023 were 146,506 and 122,412, respectively.